Once the production line is operational, it has the capability to produce up to 30 million doses of vaccines per month.
Thorsten Meincke, member of the management board for air and ocean freight at DB Schenker: “With our expertise in intercontinental transports, we want to support the global fight against the pandemic by building up vaccine production capacities where possible.
“More than ever, logistics truly matters. We are proud to be able to realize short-term air freight solutions for our customers even in times of limited market capacities.”
John Cook, vice president of manufacturing operations of Nexus Pharmaceuticals: “Nexus Pharmaceuticals is keenly aware of the need for an increase in global vaccine production capabilities and as such has aggressively taken steps to address the situation.
“The filling line and associated isolator represent critical pieces and their arrival is the culmination of Nexus’ commitment to addressing medical needs during the pandemic.
“Nexus’ investment with DB Schenker’s tremendous support was instrumental in the fast-tracking of the commissioning of our state-of-the-art sterile pharmaceutical manufacturing facility.”